This latter point is of particular importance as a current therapy, imiquimod (used in the treatment actinic keratosis and some cSCC), is associated with enhancing IFN-γ production to mount an effective immune response (40) through altering effector T cell responses (41). Here, IFNG is linked to actinic keratosis.